Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its
A comprehensive digital approach to helping patients manage type 2 diabetes, combining continuous glucose monitoring (CGM) devices, wearables and a mobile app, has been sh
An independent NICE committee has recommended that thousands of people with type 1 diabetes who can’t control the condition with current glucose monitoring and insulin pum
More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS.
Abbott is already a big player in the wearable glucose-monitoring sector, and has started working on a new device that will measure both glucose and ketones, potentially serving as a warnin
More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, acco
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.